Vijaya Diagnostic Centre Ltd

abrdn Asia Ltd, on behalf of various funds it manages, has disclosed the sale of 133,199 shares in Vijaya Diagnostic Centre Limited. This transaction, executed via open market sale on June 29, 2026, resulted in a decrease of 0.1294% in their total shareholding. Following the sale, abrdn Asia Ltd's total holding in Vijaya Diagnostic Centre stands at 3,331,046 shares, representing 3.2373% of the total share capital.

Vijaya Diagnostic Centre Ltd has announced the closure of its trading window for dealing in securities. The window will be closed effective July 1, 2026, for all designated persons (DP) and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window is set to reopen 48 hours after the announcement of the company's unaudited financial results for the quarter ending June 30, 2026. The exact date of the board meeting to declare these results will be communicated later. All DPs and their relatives are advised against trading in the company's securities during this period.

Vijaya Diagnostic Centre Ltd announced the resignation of its Chief Technology Officer (CTO), Mr. Sai Siva Prasad, due to personal reasons. His last day of employment will be August 8, 2026. The company expressed appreciation for his contributions. This marks a significant management change within the organization's technology leadership.

Mr. Ankit Shah has resigned as the Chief Financial Officer (CFO) of Vijaya Diagnostic Centre Ltd due to personal reasons. His last day of employment will be on or before July 24, 2026. The company expressed appreciation for his contributions and is ensuring a smooth transition. This change is effective as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Vijaya Diagnostic Centre Ltd has appointed Mr. Satyanaryana Murthy Chavali and Mr. Dipinder Singh Sekhon as Non-Executive Independent Directors for terms of 5 and 2 years respectively, effective from May 26, 2026, subject to shareholder approval. Mr. Chavali has experience in the pharmaceutical industry, while Mr. Sekhon is a technology entrepreneur in AI and medical imaging.

Vijaya Diagnostic Centre Ltd announced Q4 FY26 and FY26 results, reporting a 26.6% and 19.5% YoY revenue growth, respectively. Q4 FY26 revenue reached ₹2,193.8 Mn, with a PAT of ₹479.3 Mn. FY26 revenue stood at ₹8,142.0 Mn, with a PAT of ₹1,729.8 Mn. The company's network of centers has doubled, and it plans to add 4-5 hubs and 10-12 spokes in FY27, along with introducing advanced genomic testing capabilities.

Vijaya Diagnostic Centre Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. A final dividend of ₹2 per equity share (200% on face value of ₹1) was recommended, subject to shareholder approval. Dr. D Nageshwar Reddy will not seek re-appointment as an Independent Director. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY 2026-27. The company also granted 1,79,500 ESOPs and approved the acquisition of MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP.

Vijaya Diagnostic Centre Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. A final dividend of ₹2 per equity share (200% on face value of ₹1) was recommended, subject to shareholder approval. Dr. D Nageshwar Reddy will not seek re-appointment as an Independent Director. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY 2026-27. The company also granted 1,79,500 ESOPs and approved the acquisition of MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP.

Vijaya Diagnostic Centre Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. A final dividend of ₹2 per equity share (200% on a face value of ₹1) was recommended, subject to shareholder approval. Dr. D Nageshwar Reddy will not seek re-appointment as an Independent Director. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY 2026-27. The company also granted 1,79,500 ESOPs and approved the acquisition of MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP.

Vijaya Diagnostic Centre Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. A final dividend of ₹2 per equity share (200% on face value of ₹1) was recommended, subject to shareholder approval. Dr. D Nageshwar Reddy will not seek reappointment as an Independent Director. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY 2026-27. The company also granted 1,79,500 ESOPs and approved the acquisition of MRI, EEG, and NCV Services Business from Medinova Millennium MRI Services LLP.